Chapter 21. ( in part and without the tables)

For Physicians

The current metabolic panels were derived in the 1970s, during the great fats diversion and they are not sensitive enough to diagnose Fructose Toxicity”

This chapter offers a concise, practical approach to screening for fructose-induced metabolic dysfunction using accessible laboratory tools. It includes U.S.-based CPT codes, ICD-10 diagnostic codes, along with a universal disclaimer that these tables are for educational purposes only. In the final section of this chapter are biographies of leading experts in the field.


21.1 The Modern Metabolic Panel

Fructose has emerged as one of the most powerful metabolic disruptors of our time. As this book has shown, its effects are not isolated to the liver or the pancreas, nor can they be tracked with a single fasting glucose test. The true damage lies in the confluence of hepatic steatosis, insulin resistance, uric acid elevation, adipose inflammation, autonomic disruption, and cardio-metabolic remodeling. Physicians in every specialty—not just endocrinologists—are now encountering patients whose conditions stem from this common toxic exposure.


21.2 Diagnosing the Metabolic Syndrome: Definitions and Thresholds

Although various definitions of metabolic syndrome exist—from the ATP III to IDF criteria—they all converge on five domains: abdominal obesity, hyperglycemia, hypertension, hypertriglyceridemia, and low HDL. Fructose affects all five. Central obesity and hepatic fat are driven by de novo lipogenesis; uric acid and salt sensitivity raise blood pressure; and insulin resistance impairs glucose disposal.


21.3 Diagnosing MASLD and Early Liver Injury

Formerly known as NAFLD, the rebranded term MASLD (metabolic dysfunction–associated steatotic liver disease) requires not a liver biopsy but a simple constellation of risk markers. ALT elevation, abdominal imaging, and insulin resistance often suffice. Yet many physicians fail to screen at all.
For clinicians wishing to flag early uric acid excess without overt gout, the most practical approach may be to use ICD-10 code E79.0 (Hyperuricemia, without signs of gout).


21.4 Cardio-metabolic Complications of Fructose

Patients presenting with visceral adiposity, elevated triglycerides, and low HDL—especially in conjunction with hepatic steatosis or hyperuricemia—should be assumed to be in a state of accelerated cardio-metabolic risk.

Clinical Implication:
Fructose-related metabolic dysfunction may precede overt diabetes by years. However, its vascular consequences—arterial stiffness, endothelial injury, and cardiac remodeling—are already underway. Fructose-related disease does not appear in a vacuum. The patient may present with fatigue, high triglycerides, hypertension, or recurrent gout. But beneath these signals lies a single root cause: toxic overexposure to added sugars—primarily from processed food.

The old dogma that uric acid elevation is caused by purines and alcohol ignores the massive amount of fructose in the diet that has displaced alcohol and purines as the foremost cause of uric acid elevation. Uric acid elevation is linearly related to fructose intake, and uric acid is the biochemical marker for fructose toxicity. . It is no longer enough to prescribe allopurinol and colchicine, along with a dose of sympathy for the joint pains. Instead this highly significant metabolic marker should prompt a metabolic investigation for any uric acid level above 5.5 mg/dl.

Fructose is a metabolic toxin. But it is also invisible. There is no ICD-10 code for “fructose toxicity.” No CPT code for “sugar poisoning.” The job of the physician, then, is to read between the lines. To see the TyG index before the HbA1c. To consider ALT before the biopsy. To look at a patient’s diet with the same vigilance we apply to alcohol or tobacco. Because fructose is now just as dangerous—and just as common.


21.8 Applying genetic vulnerabilities to practice

In modern medicine, the acronym, GDMT stands for Guideline-Directed Medical Therapy—a clinical phrase that embodies the promise of structured, evidence-based care. Yet for all its precision, GDMT has often been applied in a one-size-fits-all manner, assuming universal biology in a genetically diverse world.

When it comes to nutrition, especially in metabolic disease, the guidelines themselves have at times lagged behind the science or ignored cultural and genetic nuance altogether.
There is one exception, and that is the Nephrologists, who, in their 2024 Guidelines of the American Society of Nephrology, incorporate this concept as illustrated with this graphic, below:

What if we rephrased the acronym? What if GDMT stood instead for Gene-Directed Metabolic Therapy—a personalized, ancestry-aware approach that honors the evolutionary inheritance of each individual?

Knowledge about processed foods and the genetic susceptibility of our patients can be easily determined in a matter of seconds with hand held artificial intelligence tools. (See the image below)

The Question to insert into an AI ChatBox is “With Ethnic Group A plus Ethnic Group B, and a small input from Ethnic Group C, list the genes, their significance, the good food and the bad food.” In seconds your patient’s probable genes and disease risks are displayed.

In this model, Pacific Islanders with CREBRF variants would avoid fructose like a toxin. South Asians with TCF7L2 would steer away from excess starch. Europeans with APOE4 would minimize saturated fats, while Arctic peoples would return to fat-rich ancestral patterns. This is not guesswork—it is the convergence of genomics, history, and public health